This interview with Neil Kelleher, Consortium President, explains the importance of Top-Down Proteomics for understanding biology and accelerating drug discovery efforts.
https://www.topdownproteomics.org/wp-content/uploads/2018/08/CTDP-logo1-w-tagline-300x152.jpg00Paul Danishttps://www.topdownproteomics.org/wp-content/uploads/2018/08/CTDP-logo1-w-tagline-300x152.jpgPaul Danis2018-01-08 17:31:082018-02-09 21:54:32Why Should We Weigh Every Protein in the Human Body?
Preliminary results from 25-laboratory study demonstrate the capabilities of top-down mass spectrometry for detailing monoclonal antibody structure and modifications. The presentation is Monday, June 5 at the Top-Down Proteomics Workshop at the ASMS Conference in Indianapolis, IN
CAMBRIDGE, MA–(Marketwired – May 31, 2017) – The Consortium for Top-Down Proteomics will present the preliminary results from their inter-laboratory study for characterizing monoclonal antibodies (mAbs) by top-down mass spectrometry techniques on June 5, 2017 at the upcoming American Society for Mass Spectrometry Annual Conference. With the continuing growth in the development and adoption of mAbs for a wide range of therapeutic uses, there is increasing demand for higher quality characterization of these complex species. This study is assessing the state of the art for providing critical information on these important materials. Read more
https://www.topdownproteomics.org/wp-content/uploads/2018/08/CTDP-logo1-w-tagline-300x152.jpg00Paul Danishttps://www.topdownproteomics.org/wp-content/uploads/2018/08/CTDP-logo1-w-tagline-300x152.jpgPaul Danis2017-05-31 00:00:122018-02-09 21:55:21The Consortium for Top-Down Proteomics to Present Monoclonal Antibodies Study at ASMS 2017
Twenty-five laboratory study to illustrate the capabilities of top-down mass spectrometry in detailing monoclonal antibody structure and modifications
CAMBRIDGE, MA–(Marketwired – February 28, 2017) – The Consortium for Top Down Proteomics today announced the launch of their inter-laboratory study for characterizing monoclonal antibodies (mAbs) by top-down mass spectrometry techniques. With the continuing growth in the development and adoption of mAbs for a wide range of therapeutic uses, there is increasing demand for higher quality characterization of these complex species.
https://www.topdownproteomics.org/wp-content/uploads/2018/08/CTDP-logo1-w-tagline-300x152.jpg00Paul Danishttps://www.topdownproteomics.org/wp-content/uploads/2018/08/CTDP-logo1-w-tagline-300x152.jpgPaul Danis2017-02-28 00:00:052018-02-09 21:55:37Consortium for Top-Down Proteomics Launches Pilot Project for Characterization of Monoclonal Antibodies
Why Should We Weigh Every Protein in the Human Body?
This interview with Neil Kelleher, Consortium President, explains the importance of Top-Down Proteomics for understanding biology and accelerating drug discovery efforts.
The Consortium for Top-Down Proteomics to Present Monoclonal Antibodies Study at ASMS 2017
Preliminary results from 25-laboratory study demonstrate the capabilities of top-down mass spectrometry for detailing monoclonal antibody structure and modifications. The presentation is Monday, June 5 at the Top-Down Proteomics Workshop at the ASMS Conference in Indianapolis, IN
CAMBRIDGE, MA–(Marketwired – May 31, 2017) – The Consortium for Top-Down Proteomics will present the preliminary results from their inter-laboratory study for characterizing monoclonal antibodies (mAbs) by top-down mass spectrometry techniques on June 5, 2017 at the upcoming American Society for Mass Spectrometry Annual Conference. With the continuing growth in the development and adoption of mAbs for a wide range of therapeutic uses, there is increasing demand for higher quality characterization of these complex species. This study is assessing the state of the art for providing critical information on these important materials. Read more
Consortium for Top-Down Proteomics Launches Pilot Project for Characterization of Monoclonal Antibodies
Twenty-five laboratory study to illustrate the capabilities of top-down mass spectrometry in detailing monoclonal antibody structure and modifications
CAMBRIDGE, MA–(Marketwired – February 28, 2017) – The Consortium for Top Down Proteomics today announced the launch of their inter-laboratory study for characterizing monoclonal antibodies (mAbs) by top-down mass spectrometry techniques. With the continuing growth in the development and adoption of mAbs for a wide range of therapeutic uses, there is increasing demand for higher quality characterization of these complex species.
Read more